Company profile
Boehringer Ingelheim
Private pharma
Privately held: no public share price · Germany
Assets
(37 total)
37Total Assets
11Approved
12Phase 3 / Filed
14Phase 1–2 / Early
18Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | EGFR/HER1, HER2, HER4Small molecule | Non-Small Cell Lung Cancer | |
Empagliflozin(Jardiance) | Approved | SGLT2Small molecule | Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease |
Linagliptin(Tradjenta) | Approved | DPP-4Small molecule | Type 2 Diabetes |
| Approved | Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
| Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
Pramipexole(Sifrol/Mirapex) | Approved | dopamineSmall molecule | Parkinson's Disease |
Pramipexole ER (Mirapex ER)(Mirapex ER) | Approved | dopamineSmall molecule | Parkinson's Disease |
spesolimab(Spevigo (approved elsewhere, for GPP)) | Approved | IL-36 receptorMonoclonal antibody | Atopic DermatitisPsoriasis |
| Approved | Muscarinic acetylcholine receptor (M3) · M3 muscarinic acetylcholine receptor · Muscarinic acetylcholine receptor, subtype M3Small molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
Tipranavir(Aptivus) | Approved | HIV proteaseSmall molecule | HIV |
| Approved | HER2 · HER2 Mutant-selectiveSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | TRPC6 (transient receptor potential cation channel subfamily C member 6)Small molecule | Chronic Kidney Disease | |
Ba253BINEBNo recent activity | Phase 3 | Muscarinic acetylcholine receptor (M3)Small molecule | Asthma |
Berodual® MA HFANo recent activity | Phase 3 | Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorSmall molecule | Asthma |
BI 1026706No recent activity | Phase 3 | Undisclosed / early pipeline | Indication not yet linked |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.